.Attribute Medication, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for addition of individuals with MASLD as well as measurement of liver outcomes in cardio-- renal-- metabolic tests, when information suggest mechanistically tenable advantages as well as scientific safety-- and outlines considerations for test concept as well as regulatory commendation.